Macrophages depletion alleviates lung injury by modulating AKT3/GXP4 following ventilator associated pneumonia.
Akt3
VAP
immunomodulation
lung cancer
macrophage
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
07
2023
accepted:
14
08
2023
medline:
22
9
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
epublish
Résumé
AKT3 appears to play a role in lung cancer. However, its role in ventilator-associated pneumonia is still unclear. Therefore, this study aimed to investigate the role of AKT3 in macrophages during ventilator-associated pneumonia. The mRNA level of AKT3, Data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), The data is analyzed using the Xiantao academic analysis tool. Additionally, the roles of AKT3 in ventilator-associated pneumonia (VAP) were investigated through AKT3 was differentially expressed in various normal and tumor tissues. Functional enrichment analysis indicated the immunomodulatory function and inflammatory response of AKT3 in lung cancer. Depletion of macrophages protected against lung epithelial cells and significantly decreased MMP9, MMP19, FTH, and FTL expression levels and increased GPX4 expression levels, while partially reversing the changes in macrophage. Mechanistically, macrophage depletion attenuates ferroptosis of lung epithelial cells by modulating AKT3 following VAP. Collectively, this study suggests the need for further validation of the immunoregulatory function of AKT3 in lung cancer. Additionally, macrophage depletion mitigates lung injury by modulating the AKT3/GPX4 pathway in the context of VAP.
Sections du résumé
Background
AKT3 appears to play a role in lung cancer. However, its role in ventilator-associated pneumonia is still unclear. Therefore, this study aimed to investigate the role of AKT3 in macrophages during ventilator-associated pneumonia.
Methods
The mRNA level of AKT3, Data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), The data is analyzed using the Xiantao academic analysis tool. Additionally, the roles of AKT3 in ventilator-associated pneumonia (VAP) were investigated through
Results
AKT3 was differentially expressed in various normal and tumor tissues. Functional enrichment analysis indicated the immunomodulatory function and inflammatory response of AKT3 in lung cancer. Depletion of macrophages protected against lung epithelial cells and significantly decreased MMP9, MMP19, FTH, and FTL expression levels and increased GPX4 expression levels, while partially reversing the changes in macrophage. Mechanistically, macrophage depletion attenuates ferroptosis of lung epithelial cells by modulating AKT3 following VAP.
Conclusion
Collectively, this study suggests the need for further validation of the immunoregulatory function of AKT3 in lung cancer. Additionally, macrophage depletion mitigates lung injury by modulating the AKT3/GPX4 pathway in the context of VAP.
Identifiants
pubmed: 37731502
doi: 10.3389/fimmu.2023.1260584
pmc: PMC10507695
doi:
Substances chimiques
AKT3 protein, human
EC 2.7.11.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1260584Informations de copyright
Copyright © 2023 Zhu, Chen, Xie, Xia, Kuang, Guo and Ning.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Science. 2018 Sep 28;361(6409):
pubmed: 30262472
Front Immunol. 2023 Mar 13;14:1148056
pubmed: 36993958
Annu Rev Immunol. 2015;33:643-75
pubmed: 25861979
Nutrients. 2022 Nov 01;14(21):
pubmed: 36364859
Redox Biol. 2022 Jun;52:102317
pubmed: 35483272
Thorac Cancer. 2021 Dec;12(23):3223-3235
pubmed: 34658165
Immunity. 2021 Jun 8;54(6):1200-1218.e9
pubmed: 33951416
Mol Biol Rep. 2020 Sep;47(9):6879-6886
pubmed: 32909215
Front Immunol. 2021 Jul 21;12:720109
pubmed: 34367190
Nat Commun. 2021 Jul 30;12(1):4624
pubmed: 34330897
Redox Biol. 2020 Sep;36:101670
pubmed: 32810738
Int J Mol Sci. 2021 Aug 18;22(16):
pubmed: 34445601
Biomed Res Int. 2022 Sep 12;2022:5794150
pubmed: 36132082
Annu Rev Pathol. 2020 Jan 24;15:123-147
pubmed: 31530089
Front Immunol. 2021 Dec 14;12:803037
pubmed: 34970275
Front Immunol. 2022 May 19;13:867260
pubmed: 35663975
FEBS J. 2022 Nov;289(22):7038-7050
pubmed: 34092035
Theranostics. 2020 Jul 23;10(20):9332-9347
pubmed: 32802195
Proc Natl Acad Sci U S A. 2022 Sep 6;119(36):e2117396119
pubmed: 36037337
Immunology. 2018 Jun;154(2):186-195
pubmed: 29455468
Nat Rev Urol. 2019 Sep;16(9):539-552
pubmed: 31278395
Mol Cell. 2022 Jun 16;82(12):2215-2227
pubmed: 35390277
Placenta. 2020 Feb;91:1-10
pubmed: 31941612
Respir Res. 2016 Aug 09;17(1):101
pubmed: 27506464
Nat Rev Mol Cell Biol. 2021 Apr;22(4):266-282
pubmed: 33495651
Cell Death Discov. 2021 Sep 29;7(1):267
pubmed: 34588431
Am J Physiol Gastrointest Liver Physiol. 2018 Jan 1;314(1):G22-G31
pubmed: 29025731
JCI Insight. 2021 Jan 11;6(1):
pubmed: 33232303
Front Med (Lausanne). 2022 May 12;9:882763
pubmed: 35646948
Respir Res. 2018 Sep 24;19(1):186
pubmed: 30249259
Redox Biol. 2019 Sep;26:101297
pubmed: 31442913
Trends Immunol. 2017 Jun;38(6):395-406
pubmed: 28396078
Cell Death Differ. 2022 Oct;29(10):1982-1995
pubmed: 35383293
Trends Cell Biol. 2020 Dec;30(12):979-989
pubmed: 33036870
Cell Death Dis. 2020 Feb 3;11(2):88
pubmed: 32015325